Strategic ownership c-LEcta is now part of Kerry Group since 2022, with Kerry acquiring a majority stake. This presents a pathway to access Kerry’s global customer base and distribution capabilities for enzyme and bioprocess solutions.

Integrated biotech hub Recent establishment of the Kerry Biotechnology Centre in Leipzig consolidates enzyme discovery, strain engineering, process development and production under one roof, enabling streamlined collaboration and faster go-to-market for partner innovations.

Core markets Target industries include food, feed, beverage and pharmaceutical sectors. These regulated markets offer clear selling points for high-purity enzyme products and engineered bioprocess solutions with potential premium pricing.

Quality pedigree ISO 9001-certified quality management since 2011 reinforces reliability and compliance, which can be leveraged to win contracts with customers requiring stringent quality standards and traceability.

Growth potential Revenue range indicates a small-to-medium enterprise with room to scale; partnerships with Kerry and expanded center capabilities can unlock larger multi-year contracts and co-development opportunities in industrial enzymes and bioprocessing.